MICb
| Drug | Organism |
---|
| |
Candida albicans
c (35)e
|
Candida albicans
d (14)e
|
---|
MIC50
| FLC | 0.125 | 64.0 (7)d
|
| ITC | 0.03 | 4.0 (13) |
| TTO | 0.125 | 0.25 |
| TERP | 0.03 | 0.06 |
| CIN | 2.0 | 4.0 |
MIC90
| FLC | 0.25 | 64.0 |
| ITC | 0.03 | 4.0 |
| TTO | 0.25 | 0.5 |
| TERP | 0.06 | 0.06 |
| CIN | 4.0 | 4.0 |
MIC range | FLC | 0.125–2.0 | 32.0–64.0 |
| ITC | 0.0078-0.5 | 4.0 |
| TTO | 0.06-0.5 | 0.25-0.5 |
| TERP | 0.015-0.06 | 0.03-0.06 |
| CIN | 1.0>4.0 | > 4.0 |
-
aFluconazole (FLC); Itraconazole (ITC); bMICs are expressed in mg/L (FLC and ITC) or in % v/v (TTO, TERP, CIN); cFLC- and ITC- susceptible isolates. The MICs for the QC of C. krusei were 32 mg/L for FLC and 0.25 mg/L for ITC, 0.25% v/v for TTO, 0.06% v/v for TERP and ≥ 4% v/v for CIN. The MICs for the QC of C. parapsilosis were 2.0 mg/L for FLC and 0.06 mg/L for ITC, 0.125% v/v for TTO, 0.03 % v/v for TERP and 4% v/v for CIN; dFLC, ITC or both, resistant isolates; six isolates were cross resistant; eIn parenthesis, the number of strains tested.